Intravenous immunoglobulin and idiopathic secondary recurrent miscarriage: a multicentered randomized placebo-controlled trial
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Idiopathic secondary recurrent miscarriage may be associated with an abnormal maternal immune response to subsequent pregnancies. Intravenous immunoglobulin (IVIG) has been studied in randomized controlled trials (RCTs) with conflicting results. Therefore, a definitive trial was proposed. METHODS: We conducted an investigator-initiated, multicentered, randomized, double-blinded, placebo-controlled trial comparing IVIG with saline in women with idiopathic secondary recurrent miscarriage, defined as a history of at least one prior ongoing pregnancy followed by three or more consecutive unexplained miscarriages. Subjects received either IVIG 500 mg/kg or the equivalent volume of normal saline. Preconception infusions were administered 14-21 days from the projected next menstrual period. With documentation of pregnancy, the subject received the same infusion every 4 weeks until 18-20 weeks of gestation. The primary outcome was an ongoing pregnancy of at least 20 weeks of gestation. RESULTS: A total of 82 patients enrolled, of whom 47 had an index pregnancy. All ongoing pregnancies resulted in live births. Therefore, the live birth rates were 70% (16/23) in the IVIG group and 63% (15/24) in the control group (P = 0.760); odds ratio (OR) 1.37 [95% confidence interval (CI) 0.41-4.61]. Including only clinical pregnancies (embryo with cardiac activity at 6 weeks of gestation), the live birth rates were equivalent, 94% (16/17) and (15/16), respectively (P > 0.999); OR 1.07 (95% CI 0.06-18.62). Meta-analysis of randomized controlled trials (RCTs) evaluating IVIG for idiopathic secondary recurrent miscarriage revealed live birth rates of 70% (31/44) in the IVIG group and 62% (28/45) in the control group (P = 0.503); common OR 1.44 (95% CI 0.59-3.48). CONCLUSIONS: This is the largest RCT to date in which IVIG was evaluated in women with idiopathic secondary recurrent miscarriage; no treatment benefit was found. The meta-analysis, which combined our study results with two prior RCTs, also showed no significant effect of treatment with IVIG.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wegmann, T. G., Lin, H., Guilbert, L., & Mosmann, T. R. (1993) · Immunology Today · doi:10.1016/0167-5699(93)90235-d · Cited by 2,852 · cited 1×
“In vitro studies suggest that pregnancy may result in uterine T-cell activation along the T-helper-2 (Th-2) pathway, resulting in blocking antibodies which mask trophoblast antigens (Wegmann et al., 1993).”
BackgroundIncidence of early loss of pregnancy
Wilcox, A. J., Weinberg, C. R., O'Connor, J. F., Baird, D. D., Schlatterer, J. P., Canfield, R. E., Armstrong, E. G., & Nisula, B. C. (1988) · New England Journal of Medicine · doi:10.1056/nejm198807283190401 · Cited by 2,354
Brandt, J. T., Triplett, D. A., Alving, B., & Scharrer, I. (1995) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1649901 · Cited by 993
Cytogenetic analysis of miscarriages from couples with recurrent miscarriage: a case-control study
Stephenson, M. D. (2002) · Human Reproduction · doi:10.1093/humrep/17.2.446 · Cited by 522
Self-citationImmunotherapy for recurrent miscarriage
Wong, L. F., Porter, T. F., & Scott, J. R. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000112.pub3 · Cited by 348
Future pregnancy outcome in unexplained recurrent first trimester miscarriage
Clifford, K., Rai, R., & Regan, L. (1997) · Human Reproduction · doi:10.1093/humrep/12.2.387 · Cited by 328
Pre-implantation endometrial leukocytes in women with recurrent miscarriage
Quenby, S., Bates, M., Doig, T., Brewster, J., Lewis-Jones, D. I., Johnson, P. M., & Vince, G. (1999) · Human Reproduction · doi:10.1093/humrep/14.9.2386 · Cited by 301
Clifford, K., Flanagan, A. M., & Regan, L. (1999) · Human Reproduction · doi:10.1093/humrep/14.11.2727 · Cited by 224 · cited 1×
“Recently, uterine CD56+/162 natural killer cells have been implicated (Lachapelle et al., 1996; Clifford et al., 1999; Quenby et al., 1999).”
Background
Cited by
Dimitriadis, E., Menkhorst, E., Saito, S., Kutteh, W. H., & Brosens, J. J. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00228-z · Cited by 702
Self-citationRecurrent pregnancy loss: current perspectives
El Hachem, H., Crepaux, V., May-Panloup, P., Descamps, P., Legendre, G., & Bouet, P.-E. (2017) · International Journal of Women's Health · doi:10.2147/ijwh.s100817 · Cited by 462
Immunotherapy for recurrent miscarriage
Wong, L. F., Porter, T. F., & Scott, J. R. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000112.pub3 · Cited by 348
Toth, B., Würfel, W., Bohlmann, M., Zschocke, J., Rudnik-Schöneborn, S., Nawroth, F., Schleußner, E., Rogenhofer, N., Wischmann, T., von Wolff, M., et al. (2018) · Geburtshilfe und Frauenheilkunde · doi:10.1055/a-0586-4568 · Cited by 119
“A few studies have pointed out that intravenous administration of immunoglobulins (IVIG) reduces the concentrations and activities of natural killer cells in peripheral blood and affects Th1-mediated immune response [97].”
Immunological Risk Factors in Recurrent Pregnancy Loss: Guidelines Versus Current State of the Art
Vomstein, K., Feil, K., Strobel, L., Aulitzky, A., Hofer-Tollinger, S., Kuon, R.-J., & Toth, B. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10040869 · Cited by 113
Metadata
- Authors
- Stephenson, M. D., Kutteh, W. H., Purkiss, S., Librach, C., Schultz, P., Houlihan, E., & Liao, C.
- Venue
- Human Reproduction
- Publisher
- Oxford University Press (OUP)
- Published
- 2010-07-15
- Volume
- 25
- Issue
- 9
- Pages
- 2203-2209
- ISSN
- 0268-1161 (ISSN-L)
- 1460-2350
- OpenAlex
- W2144437930
- Cited by
- 154
- References
- 8
- FWCI
- 3.75
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.